Request Demo

Last update 08 May 2025

UAMS Winthrop P. Rockefeller Cancer Institute

Private Company|1989|Arkansas, United States|

5,000-10,000

cancer.uams.edu

Private Company|1989|Arkansas, United States|

5,000-10,000

cancer.uams.edu

Last update 08 May 2025

Overview

Pipeline

Deal

Translational Medicine

Overview

100 Clinical Results associated with UAMS Winthrop P. Rockefeller Cancer Institute

0 Patents (Medical) associated with UAMS Winthrop P. Rockefeller Cancer Institute

Literatures (Medical) associated with UAMS Winthrop P. Rockefeller Cancer Institute

21 Apr 2025·Cancer Research

Abstract 3844: Tumor endothelial cell lines and their use for the identification of new tumor vascular targets during dysbiosis

Author: Jenkins, Samir V. ; Griffin, Robert J. ; Vang, Kieng B. ; Dings, Ruud P. ; Alimohammadi, Mohammad

AbstractThe overall use of antibiotics has increased by more than 30% in recent years according to the centers of disease control and prevention (CDC). Moreover, many cancer patients are prescribed antibiotics, as a prophylactic or to treat infection, a frequent complication during cancer progression and treatment. Yet, tumor endothelial cell lines are scarce at best and tumor endothelial cell lines derived under dysbiotic pressure non-existent. In order to address this we generated ‘normal’ or orthobiotic and dysbiotic tumor endothelial cell lines. After validating their endothelial cell origin on a genomic, proteomic and functional level, we found that tumor endothelial cells derived from dysbiotic mice (TEC-Dys) were more sensitive to hypofractionated radiation doses (i.e. 6 Gy) as compared to tumor endothelial cells derived from orthobiotic mice, TEC-Ortho. In order to identify relevant tumor vasculature drug targets during dysbiosis, we used tandem mass tag mass spectroscopy and focused on the extracellular proteins significantly overexpressed in TEC-Dys, as compared to TEC-Ortho. C-Met fulfilled these criteria and we validated this histologically by comparing tumors with or without dysbiosis. Moreover, c-Met inhibitors Foretinib, Crizotinib, and Cabozantinib were significantly more effective against TEC-Dys than TEC-Ortho. Foretinib inhibited tumor growth to a greater extend during dysbiosis as compared to orthobiotic conditions. Thus, we surmise that tumor response in dysbiotic patients may be greatly improved by targeting dysbiosis-induced pathways, such as c-Met, as compared to the targets suppressed due to dysbiosis. These matched tumor endothelial cell lines generated under orthobiotic and dysbiotic conditions can now be used in in vitro and in vivo cell-based models, and provide an improved and specialized platform for current and next-generation anti-cancer drug discovery and development.Citation Format:Samir V. Jenkins, Mohammad Alimohammadi, Kieng B. Vang, Robert J. Griffin, Ruud P. Dings. Tumor endothelial cell lines and their use for the identification of new tumor vascular targets during dysbiosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3844.

01 Dec 2024·JCO Oncology Practice

North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era

Article

Author: Leong, Man Chong ; Brogan, Frances ; Lin, Tara L. ; Cameron, Kendra ; Kasner, Margaret ; Honeycutt, Hailey ; Lee, Ji-Hyun ; Lee, Carrie B. ; Fritsche, Angela H. ; Kovak, Matthew R. ; Shaw, Kate ; George, Thomas J.

PURPOSECancer center clinical trial offices (CCTOs) support trial development, activation, conduct, regulatory adherence, data integrity, and compliance. In 2018, the Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) Steering Committee conducted and published survey results to benchmark North American CCTOs, including trial volume, accrual, full time equivalents (FTEs), and budget. The survey was readministered in 2023 to assess contemporary CCTO performance and capacity with results presented here.METHODSThe 28 question 2023 survey was sent to directors of AACI's clinical member cancer centers. Survey participation was voluntary, no compensation was provided, and data requested covered operations during 2022. Definitions were consistent with National Cancer Institute (NCI) CCTO reporting requirements and AACI staff anonymously compiled results for descriptive statistical reporting.RESULTSThe survey response rate was 61% (60/99). The median annual CCTO budget was $11.5 million (M) US dollars (USD) versus $8.2M USD in 2018. These budgets support a median of 150 FTEs versus 104 previously, and a median total of 384 versus 280 interventional treatment trials and a median of 479 versus 531 interventional treatment accruals. Sources of support for CCTO annual budgets were primarily from industry revenue (45.3%) or institutional support (31.7%). Nearly 60% of centers reported activating NCI-sponsored studies within 90 days but only 9% reported meeting a 90-day activation timeline for industry sponsored studies.CONCLUSIONContemporary benchmarks for CCTO operations through this survey demonstrate larger staff sizes, larger budgets, more trials supported, but fewer patients enrolled to interventional treatment trials in comparison with 2018. These data shine a critical light on the increasing complexity of cancer clinical trials, the importance of external funding sources, and necessary operational efficiency upgrades to provide cutting-edge cancer research and care.

22 Mar 2024·Cancer Research

Abstract 730: Leveraging microdissection for proteogenomic analysis of histological sections to advance drug development

Author: Emmert-Buck, Michael R. ; Shin, Ik Jae ; Johann, Donald J. ; Tangrea, Michael

AbstractBackground: Combining proteogenomics with laser capture microdissection (LCM) in cancer research offers a targeted way to explore the intricate interactions between tumor cells and the tumor microenvironment. This is especially important for immuno-oncology (IO) research where improvements in the predictability of patient response to IO-based drugs is sorely needed. An improved understanding of the spatial relationships involving tumor cells proper, stromal cells, blood supply and immune cell interactions may help to inform drug development and improve the indicators of success for IO-based drug regimens.Methods: LCM is used to isolate and obtain distinct histological cell types from fresh frozen tissue. Once cells have been captured, nucleic acids and proteins are extracted for in-depth multi-modality molecular profiling assays involving multiple genomic modalities and a customized solution-based mass spectrometry proteomics approach for samples or specimens with a limited amount of tissue.Results: Optimizing analysis of minute tissue quantities from LCM captured cells is challenging. Following the isolation of nucleic acids, RNA-seq may be performed for gene expression and DNA sequencing performed for the discovery and analysis of actionable mutations, copy number variation, and methylation profiles. Regarding genomic-based studies, commercial kits are often utilized for these steps due to their general availability, rapid innovation, and the robust performance of these products. However, this kit-based adaptive approach is not true for proteomics. There remains a need for highly sensitive proteomic methods targeting small-sized samples. A significant part of our proteogenomics approach is focused around an enhanced liquid chromatography mass spectrometry (LC-MS) analysis of micro-scale and/or nano-scale tissue sections. This is achieved with a silver-stained one-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (1D-SDS-PAGE) approach developed for LC-MS analysis of fresh-frozen tissue specimens obtained via LCM. This includes an in-gel digestion method adjusted and specifically designed to maximize the proteome coverage from amount-limited LCM samples to better facilitate in-depth molecular profiling.Conclusions: Reported here is a proteogenomic approach that is leveraging from microdissected fresh frozen tissue. The methodology may also be applicable to other types of specimens having limited nucleic acids, protein quantity, and/or sample volume.Citation Format: Ik Jae Shin, Michael Tangrea, Michael R. Emmert-Buck, Donald J. Johann. Leveraging microdissection for proteogenomic analysis of histological sections to advance drug development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 730.

100 Deals associated with UAMS Winthrop P. Rockefeller Cancer Institute

100 Translational Medicine associated with UAMS Winthrop P. Rockefeller Cancer Institute

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 08 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

UAMS Winthrop P. Rockefeller Cancer Institute

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 08 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing